Cancer Research Meeting Calendar Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Emdad, L.
Right arrow Articles by Fisher, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Emdad, L.
Right arrow Articles by Fisher, P. B.
[Cancer Research 66, 1509-1516, February 1, 2006]
© 2006 American Association for Cancer Research

Cell, Tumor, and Stem Cell Biology

Activation of the Nuclear Factor {kappa}B Pathway by Astrocyte Elevated Gene-1: Implications for Tumor Progression and Metastasis

Luni Emdad1, Devanand Sarkar1, Zao-zhong Su1, Aaron Randolph4, Habib Boukerche1, Kristoffer Valerie4 and Paul B. Fisher1,2,3

Departments of 1 Pathology, 2 Urology, and 3 Neurosurgery, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, New York and 4 Department of Radiation Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia

Requests for reprints: Paul B. Fisher, Department of Pathology, College of Physicians and Surgeons, Columbia University Medical Center, 630 West 168th Street, BB-1501, New York, NY 10032. Phone: 212-305-3642; -3966; Fax: 212-305-8177; E-mail: pbf1{at}columbia.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Astrocyte elevated gene-1 (AEG-1) was initially identified as an HIV-1- and tumor necrosis factor {alpha} (TNF-{alpha})–inducible transcript in primary human fetal astrocytes by a rapid subtraction hybridization approach. Interestingly, AEG-1 expression is elevated in subsets of breast cancer, glioblastoma multiforme and melanoma cells and AEG-1 cooperates with Ha-ras to promote transformation of immortalized melanocytes. Activation of the transcription factor nuclear factor {kappa}B (NF-{kappa}B), a TNF-{alpha} downstream signaling component, is associated with several human illnesses, including cancer, and NF-{kappa}B controls the expression of multiple genes involved in tumor progression and metastasis. We now document that AEG-1 is a significant positive regulator of NF-{kappa}B. Enhanced expression of AEG-1 via a replication-incompetent adenovirus (Ad.AEG-1) in HeLa cells markedly increased binding of the transcriptional activator p50/p65 complex of NF-{kappa}B. The NF-{kappa}B activation induced by AEG-1 corresponded with degradation of I{kappa}B{alpha} and nuclear translocation of p65 that resulted in the induction of NF-{kappa}B downstream genes. Infection with an adenovirus expressing the mt32I{kappa}B{alpha} superrepressor (Ad.I{kappa}B{alpha}-mt32), which prevents p65 nuclear translocation, inhibited AEG-1-induced enhanced agar cloning efficiency and increased matrigel invasion of HeLa cells. We also document that TNF-{alpha} treatment resulted in nuclear translocation of both AEG-1 and p65 wherein these two proteins physically interacted, suggesting a potential mechanism by which AEG-1 could activate NF-{kappa}B. Our findings suggest that activation of NF-{kappa}B by AEG-1 could represent a key molecular mechanism by which AEG-1 promotes anchorage-independent growth and invasion, two central features of the neoplastic phenotype. (Cancer Res 2006; 66(3): 1509-16)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
We recently reported the full-length cloning and functional characterization of an HIV-1-inducible gene, astrocyte elevated gene-1 (AEG-1), which displays slow induction kinetics following HIV infection or gp120 treatment (1–3). AEG-1 mRNA is expressed ubiquitously with higher expression in tissues containing muscular actin and its expression is increased in astrocytes infected with HIV-1 or treated with gp120 or tumor necrosis factor {alpha} (TNF-{alpha}; ref. 3). The mRNA encodes a single pass transmembrane protein of predicted molecular mass of 64 kDa and pI 9.3 that predominantly localizes in the endoplasmic reticulum and perinuclear region. Intriguingly, AEG-1 expression is elevated in subsets of breast carcinomas, malignant gliomas, and melanomas, and it synergizes with oncogenic Ha-ras to enhance soft agar colony forming ability of nontumorigenic immortalized melanocytes (3). In addition, AEG-1 expression is elevated in adult astrocytes transformed by sequential overexpression of SV40 T/t antigen, telomerase (hTERT), and T24 Ha-ras, thereby displaying an aggressive glioma-like phenotype (3). Although AEG-1 expression is not increased in all cancer cells, these results strongly suggest that AEG-1, in specific cellular contexts, may play a positive role in promoting cancer development and/or maintenance.

The transcription factor nuclear factor {kappa}B (NF-{kappa}B) regulates the expression of a wide variety of genes involved in cellular events such as inflammation, immune response, proliferation, and apoptosis (4). There are five members of the NF-{kappa}B family in mammals, including Rel (c-Rel), RelA (p65), RelB, NF-{kappa}B1 (p50 and its precursor p105), and NF-{kappa}B2 (p52 and its precursor p100; refs. 5, 6). The most abundant activated form of NF-{kappa}B is a heterodimer composed of a p50 and p65 subunit that functions predominantly as a transcriptional activator. NF-{kappa}B is present in most cells, where it remains in an inactive form in the cytoplasm bound with an inhibitory protein, I{kappa}B, which masks the nuclear localization signal. On stimulation by various NF-{kappa}B activating signals, I{kappa}B is phosphorylated and degraded through a ubiquitin-dependent process. This process frees NF-{kappa}B complex, which then translocates to the nucleus to activate transcription of downstream genes. Several recent studies indicate that NF-{kappa}B is activated by various carcinogens and tumor promoters. These include benzo[a]pyrene, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, UV radiation, ionizing radiation, and phorbol esters (7–13). For instance, UV radiation has been shown to cause sunburn reactions (swelling, leukocyte infiltration, epidermal hyperplasia, and accumulation of proinflammatory cytokines) leading to skin cancer, and suppression of NF-{kappa}B blocks the sunburn-induced damage (14). The oncogenic role of NF-{kappa}B in solid cancer has also been described in breast, colon, ovarian, thyroid, and pancreatic cancer (15–17).

TNF-{alpha} is one of the major proinflammatory cytokines and it plays an essential role in the pathogenesis of HIV-1-associated dementia by its ability to modulate the neurotransmitter glutamate-induced excitotoxicity to neurons. The excitatory amino acid transporter 2 (EAAT2) prevents glutamate toxicity by removing excess glutamate from the synaptic cleft. Treatment with TNF-{alpha} down-regulates EAAT2 mRNA and protein and also inhibits EAAT2-Prom activity in primary human fetal astrocytes (18, 19). The primary pathway by which TNF-{alpha} suppresses EAAT2 expression is by activating NF-{kappa}B (19, 20) that binds to the EAAT2 promoter and inhibits its activity. Interestingly, ectopic expression of AEG-1 also inhibits EAAT2 promoter activity. The ability of AEG-1 to promote cell transformation and inhibit EAAT2 promoter activity and the involvement of NF-{kappa}B in both of these processes prompted us to hypothesize that AEG-1 might also exert its effects by activating NF-{kappa}B.

In the present study, we report that AEG-1 markedly increases binding of the transcriptional activator p50/p65 complex of NF-{kappa}B. Inhibition of NF-{kappa}B by mt32I{kappa}B{alpha} superrepressor (I{kappa}B{alpha}-mt32) inhibits AEG-1-induced increased agar cloning efficiency and increased matrigel invasion of HeLa cells. A human NF-{kappa}B signaling pathway gene array reveals that Ad.AEG-1 infection specifically induces the expression of NF-{kappa}B dependent genes, especially the adhesion molecules involved in tumor metastasis. Furthermore, we show that TNF-{alpha} treatment results in nuclear translocation of AEG-1 and p65 wherein they physically interact. Taken together, these data suggest that AEG-1 is critically involved as a positive regulator of NF-{kappa}B-induced gene expression, and this activation may provide a molecular basis for the ability of AEG-1 to promote anchorage-independent growth and invasion, prominent contributors to cancer progression.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell lines, reagents, and virus infection protocol. The human cervical carcinoma cell line HeLa was cultured as previously described (21). The recombinant replication-incompetent adenovirus expressing AEG-1 (Ad.AEG-1) and the mt32I{kappa}B{alpha} superrepressor (Ad.I{kappa}B{alpha}-mt32; ref. 22) was created in two steps as previously described and plaque purified by standard procedures (23). These viruses were constructed as described in ref. 23 by the Massey Cancer Center Virus Vector Shared Resource. Cells were infected with a multiplicity of infection (m.o.i.) of 50 plaque-forming units (pfu)/cell of Ad.vec (control replication-incompetent adenovirus) or Ad.AEG-1 as previously described (23).

Transient transfection and luciferase assay. Cells (2 x 105 per well in 12-well plates) were either uninfected or infected with Ad.vec or Ad.AEG-1 at an m.o.i. of 50 pfu/cell and either untreated or treated with 10 ng/mL of TNF-{alpha}. Transient transfection was done 12 hours after infection using LipofectAMINE 2000 transfection reagent (Invitrogen, Carlsbad, CA) and 1.2 µg of plasmid DNA per well that included 1 µg of pGL3Basic, 3{kappa}B-Luc, or 3{kappa}Bmut-Luc plasmids (21) and 0.2 µg of ß-galactosidase expression plasmid (pSV40-ß-gal; Promega, Madison, WI). Luciferase assays were done 48 hours after transfection using a Luciferase Reporter Gene Assay kit (Promega) according to the protocol of the manufacturer. The ß-galactosidase activity was determined using the Galacto-Light Plus kit (Tropix, Bedford, MA). Luciferase activity was normalized by ß-galactosidase activity and the data presented are the fold activation relative to pGL3Basic from triplicate determinations.

Cell fractionation and electrophoretic mobility shift assay. Cells were harvested and the cytoplasm and nucleus were fractionated by the modified Schreiber's method as previously described (21). Electrophoretic mobility shift assay (EMSA) using the nuclear extracts was done as previously described (21). The sequences of the consensus and mutated NF-{kappa}B probes are 5'-AGTTGAGGGGACTTTCCCAGGC-3' and 5'-AGTTGAGGCGACTTTCCCAGGC-3', respectively (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The antibodies used for supershift analysis were anti-p50 and anti-p65 (rabbit polyclonal antibodies; Santa Cruz Biotechnology).

Reverse transcription-PCR. Total RNA was extracted from cells using the RNeasy mini kit (Qiagen, Hilden, Germany) according to the protocol of the manufacturer. Two micrograms of total RNA were used for reverse transcription-PCR (RT-PCR) according to standard methods. The primers used were as follows: interleukin (IL)-8 sense, 5'-GGTGCAGAGGGTTGTGGAGAA-3'; IL-8 antisense, 5'-GCAGACTAGGGTTGCCAGATT-3'; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense, 5'-ATGGGGAAGGTGAAGGTCGGAGTC-3'; and GAPDH antisense, 5'-GCTGATGATCTTGAGGCTGTTGTC-3'.

Western blot analysis. Whole-cell lysates and cytoplasmic as well as nuclear extracts were prepared and Western blotting was done as previously described (21). The primary antibodies used were anti-p65, anti-I{kappa}B{alpha} (rabbit polyclonal antibody; 1:250; Santa Cruz Biotechnology), anti-EF1{alpha} (mouse monoclonal antibody; 1:1,000; Upstate Biotechnology, Lake Placid, NY), and anti-AEG-1 (chicken; 1:5,000).

Immunofluorescence microscopy. Cells cultured on two-well chamber slide were infected with Ad.vec and Ad.AEG-1 at an m.o.i. of 50 pfu/cell. Forty-eight hours later, cells were fixed with 4% formaldehyde in PBS. Double immunofluorescence staining was done with anti-AEG-1 and anti-p65 antibodies as described (23) and images were taken with a confocal laser scanning microscope LSM multiphoton 510 (Zeiss, Thornwood, NY). For TNF-{alpha} experiments, cells were treated with TNF-{alpha} (10 ng/mL) for 30 minutes and then immunofluorescence staining was done as described.

Anchorage-independent growth assay. Cells were infected with Ad.vec, Ad.AEG-1, Ad.I{kappa}B{alpha}-mt32 alone (50 pfu/cell), or a combination of Ad.AEG-1 and Ad.I{kappa}B{alpha}-mt32 (50 + 50 pfu/cell). Anchorage-independent growth assays were done by seeding 1 x 105 cells in 0.4% Noble agar on a 0.8% agar base layer, both of which contained growth medium (23). Colonies were counted 2 weeks after seeding and the data from triplicate determinations were expressed as mean ± SD.

Invasion assay. Invasive ability of the cells infected with Ad.vec, Ad.AEG-1 (50 pfu/cell), or a combination of Ad.AEG-1 and Ad.I{kappa}B{alpha}-mt32 (50 + 50 pfu/cell) in vitro was determined as previously described (23). Invasion was measured by using 24-well BioCoat cell culture inserts with an 8-µ-porosity polyethylene terepthylate membrane coated with Matrigel basement membrane matrix (100 µg/cm2). Briefly, the Matrigel was allowed to rehydrate for 2 hours at room temperature by adding warm, serum-free DMEM. The wells of the lower chamber were filled with DMEM containing 5% fetal bovine serum. Cells (5 x 104) were seeded in the upper compartment (6.25-mm membrane size) in serum-free DMEM. The invasion assay was done at 37°C in a 5% CO2 humidified incubator for 48 hours. At the end of the invasion assay, the filters were removed, fixed, and stained with the RAL 555 staining kit (23). Cells on the upper surface of the filters were removed by wiping with a cotton swab and invasion was determined by counting of the cells that had migrated to the lower side of the filter with a microscope at x100 magnification. Experiments were assayed in triplicate and at least 10 fields were counted in each experiment.

Human NF-{kappa}B signaling pathway gene array. The expression levels of NF-{kappa}B signaling pathway genes after Ad.vec and Ad.AEG-1 infection were analyzed in total RNA using the Human NF-{kappa}B signaling gene array (SuperArray Biosciences Corporation, Frederick, MD) according to the protocol of the manufacturer.

Immunoprecipitation. Cells were lysed in immunoprecipitation buffer [50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, and 0.1% NP40]. After centrifugation, the supernatant was incubated with anti-hemagglutinin (HA) antibody (Covance Research Products, Inc., Berkeley, CA), anti-p65 antibody (Santa Cruz Biotechnology), or anti-AEG-1 antibody for at least 1 hour. Immunocomplexes were recovered by adsorption to protein G-Sepharose (Amersham Biosciences, Piscataway, NJ). After being washed four times in immunoprecipitation buffer, the immunoprecipitates were analyzed by immunoblotting.

Statistical analysis. Statistical analysis was done using one-way ANOVA, followed by Fisher's protected least significant difference analysis. P < 0.05 was considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Ad.AEG-1 infection generates AEG-1 protein. To confirm the authenticity of the Ad.AEG-1 construct, the expression of AEG-1 protein in HeLa cells was determined by Western blot analysis 2 days after infection with Ad.AEG-1 at an m.o.i. of 50 pfu/cell. As shown in Fig. 1A, under basal condition, expression of AEG-1 could be detected in HeLa cells and infection with Ad.AEG-1 significantly increased AEG-1 level in these cells. We have previously reported that TNF-{alpha} up-regulates AEG-1 mRNA expression. Here we show that TNF-{alpha} treatment (10 ng/mL for 4 days) also up-regulates AEG-1 expression at the protein level (Fig. 1A).


Figure 1
View larger version (32K):
[in this window]
[in a new window]
  		Figure 1. AEG-1 activates the NF-{kappa}B pathway. A, HeLa cells were either uninfected or infected with Ad.AEG-1 at an m.o.i. of 50 pfu/cell for 2 days and either untreated or treated with 10 ng/mL of TNF-{alpha} for 4 days. The expression of AEG-1 was analyzed by Western blot analysis. B, immunofluorescence microscopy with anti-AEG-1 antibody in uninfected and Ad.AEG-1 infected HeLa cells. C, HeLa cells were infected with Ad.AEG-1 (50 pfu/cell) or treated with TNF-{alpha} (10 ng/mL) and, 12 hours later, were transfected with the indicated plasmids and luciferase activity was measured as described in Materials and Methods. D, HeLa cells were infected with Ad.AEG-1 (50 pfu/cell) or treated with TNF-{alpha} (10 ng/mL) and, 2 days later, NF-{kappa}B binding activity was analyzed in the nuclear extracts of the cells by EMSA. Supershift analysis was done with the indicated antibodies. *, supershifted band by anti-p50 antibody; **, supershifted band by anti-p65 antibody.

 
Endogenous AEG-1 is localized mainly at the perinuclear region and in endoplasmic reticulum in immortalized primary human fetal astrocytes. To examine the consequences of overexpression of AEG-1 on the localization of AEG-1 protein, immunofluorescence microscopy using anti-AEG-1 antibody was done in parental HeLa cells and HeLa cells infected with Ad.AEG-1. As shown in Fig. 1B, subcellular localization of endogenous AEG-1 in HeLa cells was similar to that in immortalized primary human fetal astrocytes. However, forced overexpression of AEG-1 resulted in the localization of the protein both in the cytoplasm and in the nucleus in HeLa cells.

Infection with Ad.AEG-1 activates the NF-{kappa}B pathway. AEG-1 is overexpressed in multiple cancers and it cooperates with ras to promote transformation of melanocytes (3). AEG-1 is also induced by TNF-{alpha} treatment (2). In these contexts, we hypothesized that AEG-1 might activate the NF-{kappa}B pathway, a known TNF-{alpha}-induced signaling cascade that is activated in multiple tumors. To test whether Ad.AEG-1 infection activates the NF-{kappa}B pathway, HeLa cells were either uninfected or infected with Ad.vec or Ad.AEG-1 and then transfected with either empty vector (pGL3Basic), 3{kappa}B-Luc, containing three tandem NF{kappa}B binding sites upstream of the luciferase gene, or 3{kappa}Bmut-Luc, containing mutated NF-{kappa}B binding sites (21), and luciferase activity was analyzed. The luciferase activity was normalized by ß-galactosidase activity, which was further normalized by the activity obtained by transfection with pGL3Basic. Cells transfected with pGL3Basic showed only basal luciferase activity under any experimental condition (data not shown). In control and Ad.vec-infected cells, transfection of 3{kappa}B-Luc increased basal activity over transfection of either pGL3Basic or 3{kappa}Bmut-Luc ~5-fold, which is most likely a consequence of constitutive NF-{kappa}B DNA binding activity in HeLa cells (Fig. 1C). However, infection with Ad.AEG-1 resulted in ~15-fold induction in relative luciferase activity of 3{kappa}B-Luc over 3{kappa}Bmut-Luc (Fig. 1C). As a positive control, TNF-{alpha} treatment also induced 3{kappa}B-Luc activity ~10-fold over 3{kappa}Bmut-Luc.

NF-{kappa}B DNA binding following Ad.AEG-1 infection was analyzed by EMSA using radiolabeled consensus NF-{kappa}B binding site as a probe and nuclear extracts from HeLa cells. As shown in Fig. 1D, in uninfected and untreated cells, two shifted bands were observed. After infection with Ad.AEG-1 or treatment with TNF-{alpha}, the fast-migrating band disappeared and a marked increase in the intensity of the slow migrating band was apparent. To determine the composition of the DNA-protein complexes observed in EMSA, supershift experiments were done in which DNA-binding reactions were incubated with antibodies directed against NF-{kappa}B subunits p50 and p65. The anti-p50 antibody supershifted both the slow- and fast-migrating bands whereas anti-p65 antibody supershifted only the slow-migrating band. These findings show that under basal condition, both p50/p50 homodimer and p50/p65 heterodimer bind to the NF-{kappa}B probe. However, on Ad.AEG-1 infection and TNF-{alpha} treatment, the binding pattern changed, with the p50/p50 homodimer disappearing and the binding of the p50/p65 heterodimer increasing markedly. These findings indicate that AEG-1 is a potent activator of NF-{kappa}B because it promotes increased binding of the potent transcriptional activator p50/p65.

Overexpression of AEG-1 up-regulates NF-{kappa}B downstream genes. To confirm the functional end point of NF-{kappa}B activation by AEG-1, expression of mRNA of IL-8, a well-known NF-{kappa}B target gene, was analyzed by RT-PCR analysis after Ad.AEG-1 infection or TNF-{alpha} treatment. A significant increase in the expression of IL-8 mRNA (Fig. 2A) was detected in Ad.AEG-1-infected and TNF-{alpha}-treated HeLa cells in comparison with untreated Ad.vec-infected cells.


Figure 2
View larger version (22K):
[in this window]
[in a new window]
  		Figure 2. Ad.AEG-1 infection up-regulates NF-{kappa}B downstream genes. A, HeLa cells were infected with Ad.AEG-1 (50 pfu/cell) or treated with TNF-{alpha} (10 ng/mL) and, 2 days later, RT-PCR was done for the indicated genes. B, HeLa cells were infected with either Ad.vec or Ad.AEG-1 (50 pfu/cell) and, 2 days later, the expression of genes related to NF-{kappa}B signaling pathway was analyzed by NF-{kappa}B signaling pathway microarray as described in Materials and Methods. Graphical representation of expression levels of each gene obtained by densitometric analysis.

 
To extend these findings, expression of 113 genes related to NF-{kappa}B-mediated signal transduction was analyzed using a NF-{kappa}B signaling pathway microarray (SuperArray Biosciences) in Ad.vec and Ad.AEG-1-infected HeLa cells 2 days after infection. Ad.AEG-1 infection significantly induced the expression of several NF-{kappa}B downstream genes such as intercellular adhesion molecule (ICAM)-3, ICAM-2, selectin E, selectin P ligand, selectin L, toll-like receptor (TLR)-4, TLR-5, FOS, JUN, and IL-8 (Fig. 2B). These findings indicate that activation of NF-{kappa}B pathway by AEG-1 translates into actual changes in NF-{kappa}B-responsive gene expression.

AEG-1 activates NF-{kappa}B via I{kappa}B{alpha} degradation and p65 translocation. Classically, NF-{kappa}B is activated following the degradation of the cytoplasmic inhibitor protein I{kappa}B{alpha} that binds to the NF-{kappa}B complex. Degradation of I{kappa}B{alpha} releases NF-{kappa}B, which relocates to the nucleus to bind promoter elements and activates transcription. To determine whether AEG-1-induced NF-{kappa}B activation also proceeds through a similar pathway, the expression of I{kappa}B{alpha} was analyzed by Western blot analysis. The level of I{kappa}B{alpha} decreased significantly 48 hours after Ad.AEG-1 infection or after TNF-{alpha} treatment in comparison with Ad.vec infection in the cytoplasmic extracts of HeLa cells (Fig. 3A). In contrast, the level of the housekeeping protein EF1-{alpha} remained unchanged under all experimental conditions.


Figure 3
View larger version (49K):
[in this window]
[in a new window]
  		Figure 3. Ad.AEG-1 infection activates NF-{kappa}B by I{kappa}B{alpha} degradation and p65 nuclear translocation. HeLa cells were infected with Ad.AEG-1 (50 pfu/cell) or treated with TNF-{alpha} (10 ng/mL). A, the expressions of the indicated proteins were analyzed in cytoplasmic extracts by Western blot analysis 2 days later. B, the expressions of the indicated proteins were analyzed in cytoplasmic and nuclear extracts by Western blot analysis 2 days later. C, p65 immunostaining was evaluated by immunofluorescence microscopy after 24 hours.

 
The level of the p65 subunit of NF-{kappa}B was analyzed in cytoplasmic and nuclear extracts after Ad.AEG-1 infection and TNF-{alpha} treatment. As shown in Fig. 3B, the levels of p65 protein decreased in cytoplasmic extract and increased in the nuclear extract of cells after Ad.AEG-1 infection and TNF-{alpha} treatment in comparison with Ad.vec infection. These findings indicate that Ad.AEG-1 infection and TNF-{alpha} treatment resulted in translocation of p65 from the cytoplasm to the nucleus. Immunofluorescence studies using Anti-p65 antibody confirmed the nuclear translocation of p65 following Ad.AEG-1 infection and TNF-{alpha} treatment (Fig. 3C). Whereas high cytoplasmic and little nuclear staining for p65 was detected in Ad.vec-infected cells (Fig. 3C, left), the staining in the nucleus increased significantly in Ad.AEG-1-infected or TNF-{alpha}-treated cells with a corresponding decrease in the cytoplasmic staining (Fig. 3C, middle and right, respectively).

Inhibition of AEG-1-induced NF-{kappa}B activation blocks AEG-1-mediated anchorage-independent growth and invasion. We next evaluated the functional consequence of AEG-1-induced NF-{kappa}B activation. For this purpose, we employed an adenovirus expressing the mt32I{kappa}B{alpha} superrepressor (I{kappa}B{alpha}-mt32), Ad.I{kappa}B{alpha}-mt32, which inhibits I{kappa}B{alpha} degradation and subsequent NF-{kappa}B nuclear translocation (22). As shown in Fig. 4A, infection with Ad.I{kappa}B{alpha}-mt32 significantly inhibited both basal and Ad.AEG-1-induced NF-{kappa}B DNA binding as determined by EMSA. Additionally, infection with Ad.I{kappa}B{alpha}-mt32 dramatically reduced AEG-1-induced nuclear translocation of p65 (Fig. 4B).


Figure 4
View larger version (24K):
[in this window]
[in a new window]
  		Figure 4. Inhibition of NF-{kappa}B blocks AEG-1-induced increased anchorage independent growth. A, HeLa cells were either uninfected or infected with Ad.AEG-1 or Ad.I{kappa}B{alpha}-mt32, either alone or in combination, at an m.o.i. of 50 pfu/cell for each Ad. NF-{kappa}B DNA binding was evaluated by EMSA 2 days after infection. B, HeLa cells were infected as in (A) and, 2 days later, the level of p65 was determined in the nuclear extracts by Western blot analysis. C, HeLa cells were infected as in (A). Twenty-four hours later, cells (1 x 105) were replated in 0.4% agar on 0.8% base agar. Two weeks later, colonies >50 cells were counted under a dissection microscope. Columns, mean of triplicate plates in three independent experiments; bars, SD.

 
We previously showed that AEG-1 synergizes with oncogenic Ha-ras to enhance soft agar colony-forming ability of nontumorigenic immortalized melanocytes (3). Because NF-{kappa}B induces a variety of genes that play an important role in invasion and metastases of cancer cells, we next explored the involvement of the activated NF-{kappa}B pathway in AEG-1-induced anchorage-independent growth and invasion. HeLa cells were infected with Ad.AEG-1 and Ad.I{kappa}B{alpha}-mt32, either alone or in combination, and anchorage-independent growth in soft agar was analyzed. AEG-1-overexpressing cells developed more colonies in soft agar (Fig. 4C) than control or Ad.vec-infected cells. Overexpression of I{kappa}B{alpha}-mt32 significantly inhibited the AEG-1-induced increase in anchorage-independent growth, indicating a potential involvement of activated NF-{kappa}B pathway in this phenomenon.

In correlation with growth in soft agar, overexpression of AEG-1 significantly enhanced the invasive ability of the cells as revealed by matrigel invasion assay (Fig. 5A and B). This increased invasion was inhibited on co-infection with Ad.I{kappa}B{alpha}-mt32, further strengthening the involvement of the activated NF-{kappa}B pathway in AEG-1-induced migration and invasion.


Figure 5
View larger version (40K):
[in this window]
[in a new window]
  		Figure 5. Inhibition of NF-{kappa}B blocks AEG-1-induced enhanced matrigel invasion. A, HeLa cells were infected as in Fig. 4A. Twenty-four hours later, cells (2.5 x 104) were seeded onto the upper chamber of a matrigel invasion chamber system in the absence of serum. Forty-eight hours after seeding, the filters were fixed, stained, and photographed as described in Materials and Methods. B, graphical representation of the invasion assay. Columns, mean of three independent experiments; bars, SD.

 
AEG-1 interacts with the p65 component of NF-{kappa}B. TNF-{alpha} induces nuclear translocation of p65 and up-regulates AEG-1. AEG-1 also induces p65 nuclear translocation and Ad.AEG-1 infection results in the accumulation of AEG-1 protein in the nucleus (Fig. 1B). These findings provided a rationale to investigate whether the localization of AEG-1 is similarly altered by TNF-{alpha} treatment. We evaluated the subcellular localization of AEG-1 in HeLa cells by immunofluorescence microscopy with or without TNF-{alpha} treatment. As previously reported (3) and as shown in Fig. 6A (middle, top row), AEG-1 localized primarily in the cytoplasm. Following treatment with TNF-{alpha} for 30 minutes, a significant level of AEG-1 (Fig. 6A, middle, bottom row) was observed to accumulate in the nucleus, similar to p65 (Fig. 6A, left, bottom row). These results suggest that at least a portion of cytoplasmic AEG-1 enters the nucleus in a TNF-{alpha}-dependent manner. The nuclear translocation of AEG-1 was further confirmed by Western blot analysis done using cytoplasmic and nuclear extracts of HeLa cells, either untreated or treated with TNF-{alpha}, showing an increased level of AEG-1 in the nucleus on TNF-{alpha} treatment (Fig. 6B).


Figure 6
View larger version (40K):
[in this window]
[in a new window]
  		Figure 6. AEG-1 interacts with the p65 component of NF-{kappa}B in the nucleus. A, HeLa cells were either untreated (top row) or treated with TNF-{alpha} for 30 minutes (bottom row) and indirect immunofluorescence analysis was done. The antibodies used were anti-p65 (left, green) and anti-AEG-1 (middle, red). Right, merged images of green and red signals. B, HeLa cells were either untreated or treated with 10 ng/mL of TNF-{alpha} for 48 hours. Nuclear and cytoplasmic extracts were prepared and Western blot analysis was done with anti-AEG-1 antibody. C, HeLa cells were either untreated or treated with 10 ng/mL of TNF-{alpha} for 30 minutes. Immunoprecipitation was done in the cell lysates using anti-AEG-1 antibody. The immunoprecipitates were subjected to SDS-PAGE and Western blottings were done using anti-p65 and anti-AEG-1 antibodies. D, HeLa cells were either untransfected or transfected with AEG-1-HA and p65 expression vectors. Immunoprecipitation was done in the cell lysates using anti-p65 antibody (top two rows) or anti-HA antibody (bottom row). The immunoprecipitates were subjected to SDS-PAGE and Western blottings were done using anti-HA antibody (top row) or anti-p65 antibody (bottom two rows).

 
Merging of the immunofluorescent images for AEG-1 and p65 showed intense yellow staining in the nucleus on TNF-{alpha} treatment (Fig. 6A, right, bottom row), indicating a potential colocalization of AEG-1 and p65 in the nucleus. These observations prompted us to check whether AEG-1 and p65 interact with each other by immunoprecipitation assay. Immunoprecipitation with anti-AEG-1 antibody did not pull down p65 in untreated cells (Fig. 6C). However, with TNF-{alpha} treatment for 30 minutes, a significant level of p65 was immunoprecipitated by anti-AEG-1 antibody, indicating that TNF-{alpha} treatment results in nuclear tranlocation of p65 and AEG-1 wherein these two proteins physically associate. These findings also indicate that by interacting with p65, AEG-1 might directly augment the transcriptional activity of the NF-{kappa}B complex.

To further confirm the physical interaction between AEG-1 and p65, we transiently transfected HeLa cells with expression constructs encoding HA-AEG-1 and the p65 subunit of NF-{kappa}B. Forty-eight hours posttransfection, whole-cell lysates were used in coimmunoprecipitation assays using anti-p65 antibody. After extensive washing, the immunoprecipitates were subjected to SDS-PAGE followed by Western blotting, using anti-HA antibody. Anti-p65 antibody immunoprecipitated both endogenous and exogenous p65 protein (Fig. 6D, middle). When both p65 and HA-AEG-1 were overexpressed, AEG-1 was coimmunoprecipitated by anti-p65 antibody, indicating that AEG-1 and p65 interact in vivo (Fig. 6D, top). In addition, using the HA antibody, we successfully immunoprecipitated p65 from AEG-1- and p65-overexpressing cells but not from control cells (Fig. 6D, bottom), further confirming the in vivo interaction of AEG-1 and p65.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We presently show that AEG-1 activates the NF-{kappa}B pathway and interacts with the p65 component of NF-{kappa}B in the nucleus of HeLa cells. Under basal condition, AEG-1 is a cytoplasmic protein located predominantly in the perinuclear region and in the ER. However, on TNF-{alpha} treatment, which up-regulates AEG-1 expression, or following forced overexpression of AEG-1, accumulation of AEG-1 in the nucleus was observed together with translocation of p65 to the nucleus where these two proteins interacted. We did not detect any interaction between p65 and AEG-1 under basal condition when they are located in the cytoplasm, further strengthening the observation that nuclear translocation is necessary to facilitate this interaction. Analysis of the amino acid sequence of AEG-1 reveals the presence of putative, either monopartite or bipartite, nuclear localization signal between amino acids 432 to 451 and amino acids 561 to 580 (Table 1). It is still not clear how AEG-1 is retained in the cytoplasm and how, on TNF-{alpha} treatment or on AEG-1 overexpression, the nuclear localization signal is unmasked and the protein translocates into the nucleus. Conceptually, it is possible that AEG-1 interacts with an inhibitory protein like I{kappa}B{alpha} in the cytoplasm, and AEG-1 itself, as well as TNF-{alpha}, might trigger a signaling event that results in the degradation of this interacting protein as well as I{kappa}B{alpha} that facilitates the unmasking of nuclear localization signal of both AEG-1 and p65. These hypotheses are analogous to the nuclear receptor coactivator SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) that is located mainly in the cytoplasm, translocates from the cytoplasm to the nucleus on TNF-{alpha} activation, and enhances NF-{kappa}B-mediated gene expression (24). Current studies are in progress to identify AEG-1-interacting molecules to provide a better understanding of the molecular mechanism of AEG-1 action.


View this table:
[in this window]
[in a new window]
  		Table 1. AEG-1 contains nuclear localization signal

 
A separate group also cloned human AEG-1 as metadherin and the cloning of the mouse (3D3) and rat (lyric) homologues of AEG-1 has been reported. Rat lyric was reported as an overexpressed gene in rat liver and colon tumors (3). As a corollary, human metadherin manifested high expression in breast cancer cells and contains a lung-homing domain that facilitates metastasis of the breast cancer cells to the lungs. We also detected elevated levels of AEG-1 in subsets of breast cancer, glioblastoma multiforme, and melanoma cells, and ectopic expression of AEG-1 promoted colony forming ability of immortalized melanoma cells (3). These findings indicate that in both human and rat, AEG-1 is involved in promoting tumor progression and metastasis, and we now elucidate, for the first time, that NF-{kappa}B-dependent gene expression changes play a crucial mechanistic role in mediating augmentation of tumorigenic potential by AEG-1. We show that AEG-1 facilitates I{kappa}B{alpha} degradation, resulting in an increase in NF-{kappa}B DNA binding activity and NF-{kappa}B promoter activity in reporter assays. Additionally, we show that inhibition of NF-{kappa}B by I{kappa}B{alpha}-mt32 significantly inhibits AEG-1-induced augmentation in soft agar colony formation and invasion of HeLa cells. Several different tumor cell types, including leukemia, lymphoma, myeloma, melanoma, prostate, colon, breast, pancreas, glioma, and head and neck squamous cell carcinoma cell lines, as well as samples obtained from cancer patients, have been reported to express constitutively active NF-{kappa}B (15–17, 25–27). Inhibition of p65 by specific antisense oligonucleotides successfully reduced the growth of cancer cells. It will be interesting to determine whether the constitutive activation of NF-{kappa}B in these cells is a result of increased AEG-1 expression and whether inhibition of AEG-1 by an antisense or siRNA strategy might ablate the tumorigenic potential of these cells by inhibiting constitutive NF-{kappa}B activation.

NF-{kappa}B is a ubiquitously expressed transcription factor for genes involved in cell survival, cell adhesion, inflammation, differentiation, and growth (28–31). In intestinal epithelial cells, the responses to NF-{kappa}B activation include the production of cytokines and chemokines (IL-1ß, IL-6, IL-8, and macrophage inflammatory protein-2), cell-surface receptors (IL-2 receptor), adhesion molecules (ICAM-1), inflammatory enzymes (inducible nitric oxide synthase and cyclooxygenase 2), stress proteins (complement factors B, C3, and C4), and immunoregulatory molecules (MHC I and MHC II; ref. 32). A human NF-{kappa}B signaling pathway gene array revealed that Ad.AEG-1 infection resulted in marked up-regulation of NF-{kappa}B-responsive cell adhesion molecules (ICAM-2 and ICAM-3, selectin E, selectin L, and selectin P ligand), TLR4 and TLR5, and cytokines such as IL-8 (Fig. 2B). What is the significance of induction of these genes by AEG-1 in the context of tumorigenesis and HIV infection? ICAM-2 and ICAM-3 are frequently overexpressed in B-cell chronic lymphocytic leukemia (33). ICAM-3 exerts numerous functions in T-cell adhesion, polarization, and activation during the immune response (34–36). Previous studies suggest that ICAM-3 acts as a costimulatory molecule to increase HIV-1 transcription and viral production, a process allowing productive infection in quiescent CD4+ T lymphocytes (37). Our observations with the cytokine array that infection with Ad.AEG-1 markedly upregulated ICAM-3 production (34.44-fold over control) suggest that AEG-1 might act as a molecule in the positive feedback loop to further promote HIV replication. E-selectin was shown to regulate the attachment of a colon carcinoma cell line to endothelial cells in vitro (38) whereas P-selectin has been shown to bind to various types of carcinoma cells (39). High levels of soluble E-selectin have also been reported in melanoma and some epithelial tumors (40). Similarly, L selectin has been identified as a possible predictor of the hematogenous dissemination of murine lymphomas (41). Infection with Ad.AEG-1 produced a marked up-regulation of all of the above-mentioned selectins, uncovering a potential mechanism of AEG-1-mediated enhanced lung metastasis of breast cancer cells and increased adhesion of immortalized melanocytes to lung endothelial cells (data not shown). AEG-1 also induced significant up-regulation of TLR4 (42), which has been implicated in tumor cell immune evasion. Blockade of the TLR4 pathway by either TLR4 short interfering RNA or a cell-permeable TLR4 inhibitory peptide reverses tumor-mediated suppression of T-cell proliferation and natural killer cell activity in vitro and in vivo, delays tumor growth, and thus prolongs the survival of tumor-bearing mice. The observation that AEG-1 induces certain cell adhesion molecules that are intimately involved in tumor metastasis suggests a potential involvement of AEG-1 in these pathologic processes.

In summary, we now document that AEG-1 induces increased anchorage-independent growth and invasiveness of tumor cells and increased expression of adhesion molecules by activating the NF-{kappa}B pathway, and we hypothesize that these fundamental physiologic changes promoted by this gene might be important components of tumor progression and metastasis. Moreover, we have shown that AEG-1 can physically interact with p65 and modulate its function in the nucleus. Increased insights into the detailed molecular mechanism(s) of AEG-1 action will help determine its role in the process of tumorigenesis and HIV infection and facilitate development of strategies to counteract these virulent disease states by targeting AEG-1 via an antisense or siRNA approach, or a small-molecule inhibitor, for inactivation.


   Acknowledgments
 
Grant support: NIH/NS P01 NS31492; the Samuel Waxman Cancer Research Foundation; the Chernow Endowment; and a Joelle Syverson Fellowship from the American Brain Tumor Association (L. Emdad).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   Footnotes
 
Note: P.B. Fisher is the Michael and Stella Chernow Urological Cancer Research Scientist and a Samuel Waxman Cancer Research Foundation Investigator.

Received 9/13/05. Accepted 11/14/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Su ZZ, Kang DC, Chen Y, et al. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene 2002;21:3592–602.[CrossRef][Medline]
  2. Su ZZ, Chen Y, Kang DC, et al. Customized rapid subtraction hybridization (RaSH) gene microarrays identify overlapping expression changes in human fetal astrocytes resulting from human immunodeficiency virus-1 infection or tumor necrosis factor-{alpha} treatment. Gene 2003;306:67–78.[CrossRef][Medline]
  3. Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ, Fisher PB. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene 2005;353:8–15.[CrossRef][Medline]
  4. Bharti AC, Aggarwal BB. Nuclear factor-{kappa}B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002;64:883–8.[CrossRef][Medline]
  5. Ghosh S, Karin M. Missing pieces in the NF-{kappa}B puzzle. Cell 2002;109:S81–96.
  6. Karin M, Lin A. NF-{kappa}B at the crossroads of life and death. Nat Immunol 2002;3:221–7.[CrossRef][Medline]
  7. Pahl HL. Activators and target genes of Rel/NF-{kappa}B transcription factors. Oncogene 1999;18:6853–66.[CrossRef][Medline]
  8. Yan Z, Subbaramaiah K, Camilli T, et al. Benzo[a]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. Evidence for the involvement of extracellular signal-regulated kinase and NF-{kappa}B. J Biol Chem 2000;275:4949–55.[Abstract/Free Full Text]
  9. Rioux N, Castonguay A. The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-{kappa}B. Carcinogenesis 2000;219:1745–51.
  10. Li N, Karin M. Ionizing radiation and short wavelength UV activate NF-{kappa}B through two distinct mechanisms. Proc Natl Acad Sci U S A 1998;95:13012–7.[Abstract/Free Full Text]
  11. Baeuerle PA, Lenardo M, Pierce JW, Baltimore D. Phorbol-ester-induced activation of the NF-{kappa}B transcription factor involves dissociation of an apparently cytoplasmic NF-{kappa}B/inhibitor complex. Cold Spring Harb Symp Quant Biol 1988;53:789–98.
  12. Taher M, Oakley JD, Hershey C, Valerie K. Activation of NF-{kappa}B and p38 MAP kinase is not sufficient for triggering efficient HIV gene expression in response to stress. Biochemistry 2000;39:1709–15.[CrossRef][Medline]
  13. Valerie K, Laster WS, Kirkham JC, Kuemmerle NB. Ionizing radiation activates NF-{kappa}B but fails to produce an increase in human immunodeficiency virus gene expression in stably transfected human cells. Biochemistry 1995;34:15768–76.[CrossRef][Medline]
  14. Abeyama K, Eng W, Jester JV, et al. A role for NF-{kappa}B-dependent gene transactivation in sunburn. J Clin Invest 2000;105:1751–9.[Medline]
  15. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-{kappa}B transcription factor and cancer: high expression of NF-{kappa}B- and I{kappa}B-related proteins in tumor cell lines. Biochem Pharmacol 1994;47:145–9.[CrossRef][Medline]
  16. Visconti R, Cerutti J, Battista S, et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF{kappa}B p65 protein expression. Oncogene 1997;15:1987–94.[CrossRef][Medline]
  17. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-{kappa}B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119–27.[Abstract/Free Full Text]
  18. Su ZZ, Leszczyniecka M, Kang DC, et al. Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proc Natl Acad Sci U S A 2003;100:1955–60.[Abstract/Free Full Text]
  19. Fine SM, Angel RA, Perry SW, et al. Tumor necrosis factor {alpha} inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J Biol Chem 1996;271:15303–6.[Abstract/Free Full Text]
  20. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001;11:372–7.[CrossRef][Medline]
  21. Sarkar D, Lebedeva IV, Emdad L, Kang DC, Baldwin AS, Jr., Fisher PB. Human polynucleotide phosphorylase (hPNPaseold-35): a potential link between aging and inflammation. Cancer Res 2004;64:7473–8.[Abstract/Free Full Text]
  22. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I {kappa}B-{alpha} proteolysis by site-specific, signal-induced phosphorylation. Science 1995;267:1485–8.[Abstract/Free Full Text]
  23. Su ZZ, Emdad L, Sauane M, et al. Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene 2005;24:7552–66.[CrossRef][Medline]
  24. Wu RC, Qin J, Hashimoto Y, et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I{kappa}B kinase. Mol Cell Biol 2002;22:3549–61.[Abstract/Free Full Text]
  25. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin down-regulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001;20:7597–609.[CrossRef][Medline]
  26. Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-{kappa}B in primary adult T-cell leukemia cells. Blood 1999;93:2360–8.[Abstract/Free Full Text]
  27. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-{kappa}B-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961–9.[Medline]
  28. Aggarwal BB, Vilcek J. Tumor necrosis factor: structure, function and mechanism of action. New York: Marcel Dekker Inc; 1992.
  29. Shishodia S, Aggarwal BB. Nuclear factor-{kappa}B activation: a question of life and death. J Biochem Mol Biol 2002;35:28–40.[Medline]
  30. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-{kappa}B and cytokine-inducible enhancers. FASEB J 1995;9:899–909.[Abstract]
  31. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-{kappa}B in cell growth regulation. Am J Pathol 2001;159:387–97.[Abstract/Free Full Text]
  32. Jobin C, Sartor RB. The I{kappa}B/NF{kappa}B system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000;278:C451–62.[Abstract/Free Full Text]
  33. Molica S, Dattilo A, Mannella A, Levato D. Intercellular adhesion molecules (ICAMs) 2 and 3 are frequently expressed in B cell chronic lymphocytic leukemia. Leukemia 1996;10:907–8.[Medline]
  34. Bleijs DA, Binnerts ME, van Vliet SJ, Figdor CG, van Kooyk Y. Low-affinity LFA-1/ICAM-3 interactions augment LFA-1/ICAM-1-mediated T cell adhesion and signaling by redistribution of LFA-1. J Cell Sci 2000;113:391–400.[Abstract]
  35. Campanero MR, del Pozo MA, Arroyo AG, et al. ICAM-3 interacts with LFA-1 and regulates the LFA-1/ICAM-1 cell adhesion pathway. J Cell Biol 1993;123:1007–16.[Abstract/Free Full Text]
  36. Cid MC, Esparza J, M. Juan, et al. Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in ß1 and ß2 integrin function. Eur J Immunol 1994;24:1377–82.[Medline]
  37. Barat C, Gervais P, Tremblay MJ. Engagement of ICAM-3 provides a costimulatory signal for human immunodeficiency virus type 1 replication in both activated and quiescent CD4+ T lymphocytes: implications for virus pathogenesis. J Virol 2004;78:6692–7.[Abstract/Free Full Text]
  38. Rice GE, Bevilacqua MP. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 1989;246:1303–6.[Abstract/Free Full Text]
  39. Aruffo A, Dietsch MT, Wan H, et al. Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines. Proc Natl Acad Sci U S A 1992;89:2292–6.[Abstract/Free Full Text]
  40. Uner A, Akcali Z, Unsal D. Serum levels of soluble E-selectin in colorectal cancer. Neoplasma 2004;51:269–74.[Medline]
  41. Bargatze RF, Wu NW, Weissman IL, et al. High endothelial venule binding as a predictor of the dissemination of passaged murine lymphomas. J Exp Med 1987;166:1125–31.[Abstract/Free Full Text]
  42. Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65:5009–14.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
D. Sarkar, L. Emdad, S.-G. Lee, B. K. Yoo, Z.-z. Su, and P. B. Fisher
Astrocyte Elevated Gene-1: Far More Than Just a Gene Regulated in Astrocytes
Cancer Res., November 15, 2009; 69(22): 8529 - 8535.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. N. Holcomb, J. M. Young, I. M. Coleman, K. Salari, D. I. Grove, L. Hsu, L. D. True, M. P. Roudier, C. M. Morrissey, C. S. Higano, et al.
Comparative Analyses of Chromosome Alterations in Soft-Tissue Metastases within and across Patients with Castration-Resistant Prostate Cancer
Cancer Res., October 1, 2009; 69(19): 7793 - 7802.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Hu, Y. Wei, and Y. Kang
The Multifaceted Role of MTDH/AEG-1 in Cancer Progression
Clin. Cancer Res., September 15, 2009; 15(18): 5615 - 5620.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. K. Yoo, R. Gredler, N. Vozhilla, Z.-z. Su, D. Chen, T. Forcier, K. Shah, U. Saxena, U. Hansen, P. B. Fisher, et al.
Identification of genes conferring resistance to 5-fluorouracil
PNAS, August 4, 2009; 106(31): 12938 - 12943.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. Yu, K. Chen, H. Zheng, X. Guo, W. Jia, M. Li, M. Zeng, J. Li, and L. Song
Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis
Carcinogenesis, May 1, 2009; 30(5): 894 - 901.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. J. Thirkettle, J. Girling, A. Y. Warren, I. G. Mills, K. Sahadevan, H. Leung, F. Hamdy, H. C. Whitaker, and D. E. Neal
LYRIC/AEG-1 Is Targeted to Different Subcellular Compartments by Ubiquitinylation and Intrinsic Nuclear Localization Signals
Clin. Cancer Res., May 1, 2009; 15(9): 3003 - 3013.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Catalano, R. Lazzarini, S. Di Nuzzo, S. Orciari, and A. Procopio
The Plexin-A1 Receptor Activates Vascular Endothelial Growth Factor-Receptor 2 and Nuclear Factor-{kappa}B to Mediate Survival and Anchorage-Independent Growth of Malignant Mesothelioma Cells
Cancer Res., February 15, 2009; 69(4): 1485 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Li, N. Zhang, L.-B. Song, W.-T. Liao, L.-L. Jiang, L.-Y. Gong, J. Wu, J. Yuan, H.-Z. Zhang, M.-S. Zeng, et al.
Astrocyte Elevated Gene-1 is a Novel Prognostic Marker for Breast Cancer Progression and Overall Patient Survival
Clin. Cancer Res., June 1, 2008; 14(11): 3319 - 3326.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S.-G. Lee, Z.-Z. Su, L. Emdad, P. Gupta, D. Sarkar, A. Borjabad, D. J. Volsky, and P. B. Fisher
Mechanism of Ceftriaxone Induction of Excitatory Amino Acid Transporter-2 Expression and Glutamate Uptake in Primary Human Astrocytes
J. Biol. Chem., May 9, 2008; 283(19): 13116 - 13123.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Sarkar, E. S. Park, L. Emdad, S.-G. Lee, Z.-z. Su, and P. B. Fisher
Molecular Basis of Nuclear Factor-{kappa}B Activation by Astrocyte Elevated Gene-1
Cancer Res., March 1, 2008; 68(5): 1478 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
D. E. Britt, S. Ash, and D. Yang
Defining a role for LYRIC in NF-kappaB signaling and prostate tumor progression
FASEB J, April 1, 2007; 21(6): A1151 - A1151.


Home page
 Cancer Res.Home page
H. Boukerche, Z.-z. Su, L. Emdad, D. Sarkar, and P. B. Fisher
mda-9/Syntenin Regulates the Metastatic Phenotype in Human Melanoma Cells by Activating Nuclear Factor-{kappa}B
Cancer Res., February 15, 2007; 67(4): 1812 - 1822.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Loewe, T. Valero, S. Kremling, B. Pratscher, R. Kunstfeld, H. Pehamberger, and P. Petzelbauer
Dimethylfumarate Impairs Melanoma Growth and Metastasis
Cancer Res., December 15, 2006; 66(24): 11888 - 11896.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S.-G. Lee, Z.-Z. Su, L. Emdad, D. Sarkar, and P. B. Fisher
Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc
PNAS, November 14, 2006; 103(46): 17390 - 17395.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Emdad, L.
Right arrow Articles by Fisher, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Emdad, L.
Right arrow Articles by Fisher, P. B.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online